Clinical trial NCT06513884: A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
Official title: A Randomized Double-blinded Phase 2/3 Study of HB-202/HB-201 Alternating 2-Vector Therapy With Pembrolizumab Versus Pembrolizumab-Only for First Line HPV16+ High PD-L1 CPS Recurrent and/or Metastatic Oropharyngeal Squamous Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Oropharyngeal Squamous Cell Carcinoma Recurrent
Keywords: head and neck cancer
squamous cell cancer
head and neck squamous cell carcinoma
HNSCC
oropharyngeal squamous cell carcinoma
human papillomavirus 16
HPV
programmed cell death 1 ligand 1
PD-L1
immune checkpoint inhibitor
immunotherapy
genetic vector
arenavirus
Lead sponsor: Hookipa Biotech GmbH
Sponsor class: INDUSTRY
First posted: 2024-07-22
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study of HB-202/HB-201 alternating 2-vector therapy with pembrolizumab (also known as Keytruda®) in people with human papillomavirus subtype 16 positive (HPV16+) head and neck cancer starting in the middle part of the throat, who have not yet received systemic treatment after their cancer spread (metastatic) and/or returned (recurrent) and who are eligible to receive pembrolizumab.

Doctors already use pembrolizumab therapy (with or without chemotherapy) to treat head and neck cancer. However, the treatment does not work well in most people with this type of cancer. HB-202/HB-201 alternating 2-vector therapy with pembrolizumab, which is designated to stimulate a stronger immune attack against HPV16+ tumors, was shown to be safe and suggested to work better than pembrolizumab-only in a small number of participants with HPV16+ head and neck cancer (see H-200-001, NCT04180215).

This trial studies HB-202/HB-201 alternating 2-vector therapy with pembrolizumab in a much larger number of participants from different countries to confirm its benefits for people with HPV16+ head and neck cancer that started in the middle part of the throat compared with pembrolizumab-only therapy. This trial studies whether administering HB-202/HB-201 alternating 2-vector therapy with pembrolizumab works better in more participants by shrinking their tumors and makes them live longer than pembrolizumab-only therapy.

Participants will receive the study treatments by injection into a vein every 3 weeks during the first 3 months and then every 6 weeks until up to about 2 years, which will be followed by a long observation period to continue looking at the safety and clinical benefits after the last dose of study treatment.

Detailed description: This is a seamless adaptive Phase 2/3, randomized, double-blinded, placebo-controlled, multicenter trial of HB-202/HB-201 alternating 2-vector therapy with the approved drug pembrolizumab in participants with HPV16+ recurrent and/or metastatic oropharyngeal squamous cell carcinoma (OPSCC), whose tumor has a programmed cell death ligand-1 (PD-L1) combined positive score (CPS) greater than or equal to 20 in the first line setting. OPSCC is a type of head and neck squamous cell carcinoma (HNSCC) originating in the oropharyngeal region (tonsil, tongue base, soft palate, or uvula). The study will evaluate the long-term safety and the benefits on objective response rate, overall survival, and progression-free survival of HB-202/HB-201 alternating 2-vector therapy plus pembrolizumab compared with pembrolizumab-only therapy.

Pembrolizumab-only therapy or pembrolizumab plus chemotherapy are currently the first-line therapies used to treat people with recurrent and/or metastatic HNSCC (including HPV+ OPSCC). However, poor prognosis prevails despite pembrolizumab therapy with or without chemotherapy (including patients with PD-L1 CPS greater or equal to 20), where only a minority of patients respond.

HB-202 and HB-201 are genetically engineered, replicating vectors based on the arenaviruses Pichinde virus and lymphocytic choriomeningitis virus, respectively. The HB-202 and HB-201 vectors have been engineered to deliver specific non-oncogenic antigens derived from HPV16, which enables the vectors to stimulate a strong and specific immune response against HPV16+ tumor cells. Pembrolizumab on the other hand is a potent checkpoint inhibitor, which binds to immune cell surface receptors to relieve the typical inhibition of immune surveillance of tumors. In an early phase trial (H-200-001, NCT04180215), HB-202/HB-201 alternating 2-vector therapy with pembrolizumab has shown favorable safety and preliminary anti-tumor activity with an objective response rate higher than previously reported with pembrolizumab-only therapy in participants with HPV16+ OPSCC.

HB-202/HB-201 alternating 2-vector therapy or matched placebo will be administered in treatment cycles. A treatment cycle is defined as one administration of HB-202 plus the post-dose period followed by one administration of HB-201 plus the post-dose period until the next dose. In the first 2 treatment cycles, the HB-202/HB-201 or matched placebo treatment is administered with 200 mg pembrolizumab every 3 weeks. The HB-202/HB-201 or matched placebo treatment is administered with 400 mg pembrolizumab every 6 weeks from the third treatment cycle onwards. Adverse events (AEs) will be monitored for up to 30 days and serious AEs for up to 90 days after the last dose of study treatment. There will be long-term follow-up every 3 months after the last administration of study treatment for all participants until the participant's death, the participant is lost to follow-up or withdraws consent to follow-up, last study-related phone call or visit, or study termination, whichever occurs first.

Participants will be randomized to receive either HB-202/HB-201 alternating 2-vector therapy followed by pembrolizumab or matched placebo (i.e., matched to the respective viral vector) followed by pembrolizumab.

Up to 150 Investigators and study sites in North America, Europe, and other regions of the world are expected to enroll participants in this study.

Eligibility criteria: Inclusion Criteria:

* Participants at least 18 years of age.
* Confirmed recurrent and/or metastatic OPSCC that is considered incurable by local therapies.
* Must not have had prior systemic anticancer therapy, including investigational therapy and non-palliative radiotherapy, administered in the recurrent and/or metastatic setting.
* Confirmed HPV16+ AND PD-L1+ (with a CPS greater or equal to 20) tumor, based on tumor specimen, core, or excisional biopsy samples from a tumor lesion not previously irradiated.
* Must have measurable disease based on RECIST version 1.1 as determined by BICR.
* Eastern Cooperative Oncology Group performance status must be 0 to 1.
* Adequate organ function should be confirmed within 10 days prior to the first dose of study treatment.

Exclusion Criteria:

* Has progressive disease within 6 months of completion of curatively intended systemic treatment (including checkpoint inhibitors) for locoregionally advanced OPSCC.
* Life expectancy of less than 3 months and/or rapidly progressing disease, high burden of visceral metastatic disease, or significant tumor burden in anatomically critical areas (e.g., causing significant biliary or respiratory obstruction) who may benefit from a chemotherapy-based treatment regimen.
* History or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the trial or interfere with the participant's participation for the full duration of the trial, or such that it is not in the best interest of the patient to participate, in the opinion of the treating Investigator. This includes active cardiovascular disease within 6 months before study entry.
* Is pregnant or breastfeeding or expecting to conceive or father children starting with the screening visit through a minimum of 2 months after the last dose of trial treatment.
* Was discontinued due to a Grade 3 or 4 immune-related AE after receiving prior therapy with a checkpoint inhibitor agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor.
* Received systemic steroids at a dose of \>10 mg/day (prednisone equivalent) for \<30 days within 14 days or for ≥30 days within 28 days of the first dose of study treatment.
* Received live, or live-attenuated vaccine within 30 days of the planned first dose of treatment or anticipates that such a vaccine will be required during the study.
* Participating in or has participated in a study of an investigational agent, or has used an investigational device treatment, within 4 weeks before the first dose of study treatment.
* Has had an allogeneic tissue/solid organ transplant.
* Has known immunodeficiency OR is receiving long-term systemic steroid therapy or any other form of immunosuppressive therapy within 28 days before the first dose of study treatment.
* Known additional malignancy within 2 years before the first dose of study treatment.
* Known CNS metastases and/or carcinomatous meningitis.
* Has severe hypersensitivity (Grade 3 and/or 4) to pembrolizumab and/or any of its excipients.
* Has an active autoimmune disease that has required systemic treatment in the past 2 years.
* History or current evidence of (non-infectious) pneumonitis/interstitial lung disease.
* Has an active infection requiring systemic therapy.
* Known history of acquired immunodeficiency syndrome (AIDS). Testing for human immunodeficiency virus (HIV) is not mandatory.
* Known history of hepatitis B virus (defined as hepatitis B surface antigen reactive) or known active hepatitis C virus infection (defined as hepatitis C virus ribonucleic acid \[RNA\] is detected \[qualitative\]).

Primary outcomes:
measure: Objective response rate - Blinded independent central review (BICR)
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Overall survival
timeFrame: Up to 7.5 years after first dose of study treatment
Secondary outcomes:
measure: Progression-free survival - BICR
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Duration of response - BICR
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Disease control rate - BICR
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Progression-free survival on next-line therapy
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Objective response rate - Investigator
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Progression-free survival - Investigator
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Duration of response - Investigator
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Disease control rate - Investigator
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Proportion of participants with AEs - overall
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Adjusted on-study year rate of AEs
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Proportion of participants with laboratory abnormality - overall
timeFrame: Up to 2 years after first dose of study treatment
measure: Adjusted on-study yearly rate of laboratory abnormality
timeFrame: Up to 2 years after first dose of study treatment
measure: Participant-reported health-related quality of life - European Quality of Life scale EQ-5D-3L
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Participant-reported health-related quality of life - EORTC QLQ-C30
timeFrame: Up to 7.5 years after first dose of study treatment
measure: Participant-reported health-related quality of life - EORTC QLQ-H&N35
timeFrame: Up to 7.5 years after first dose of study treatment
Other outcomes:
Locations:
Study officials:
affiliation: Hookipa Biotech GmbH
name: Head of Clinical Development
role: STUDY_DIRECTOR
References: